Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ReSearch Pharmaceutical Buys China CRO Paramax

publication date: Apr 6, 2009

ReSearch Pharmaceutical Services (RPS), a US-headquartered international CRO, will acquire Paramax International for $1 million and 530,973 shares of RPS common stock. Paramax is a CRO that is based in Beijing with offices in other China cities. RPS positioned the acquisition as an expansion of its global CRO business. The company bought three European CROs in late 2008, and it has operations in Central and South America as well. Paramax is the company’s first foray into Asia. More details..

Stock Symbol: (AIM: RPSE)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital